Generic HIV drug rollout to take a hit on trial push
India's decision to reject a waiver for local clinical trials of a new HIV drug, lenacapavir, is causing concern. Public health experts warn this will delay access to the affordable generic version for millions in India and other low-income nations. Drug maker Hetero Labs sought the waiver to speed up the launch of the treatment.